268 results about "Anticarcinogen" patented technology

The present invention provides anticancer agents comprising as an active ingredient a bispecific antibody that comprises a domain comprising a glypican 3-binding antibody variable region, a domain comprising a T cell receptor complex-binding antibody variable region, and common L chains that can enhance the affinity for the two antigens, as well as pharmaceutical compositions comprising the bispecific antibody as an active ingredient, the compositions being for use in combination with other anticancer agents. The bispecific antibodies are novel molecules which are produced with high efficiency and have strong anti-tumor activity as well as safety and excellent pharmacodynamics. The bispecific antibodies can be expected to be applied to various cancers.

Disclosed are methods of treating cancer comprising administering to a subject a treatment regimen comprising a compound of Formula (I): Formula (I), or a pharmaceutically acceptable salt thereof, and a taxane anticancer agent.

The present invention relates to a composition comprising a combination of an anti-PD-1 antibody and an additional antibody. Pharmaceutical compositions are provided, which comprise a combination of anticancer agents that are a first antibody and a second antibody. In some embodiments, the first antibody is an anti-programmed death-1 (PD-1) antibody. In certain embodiments, the composition is a fixed-dose formulation. In certain embodiments, the composition is administered in an absolute dose. The present disclosure also provides a kit for treating a subject having a disease, the kit comprising a dose of any of the compositions disclosed herein and instructions for using the composition to treat a disease in any of the disclosed methods.

[Problem] To provide a novel compound promising as a prodrug-type anticancer agent that exhibits a sufficient anticancer effect and is capable of reducing adverse effects. [Solution] A compound represented by general formula (I) or a pharmaceutically acceptable salt of the compound. Formula (I): Y-T-(X1)n

A method for treating proliferative diseases such as cancer in a subject by a combination therapy, which includes administering to the subject a pharmaceutical composition including a benzenesulfonamide derivative such as p-Toluenesulfonamide and at least one other therapeutic agents in a different classification of anticancer agents.

To provide means of suppressing immune checkpoints based on signaling pathways independent of the PD1 pathway, and to provide methods for in silico search for genes belonging to signaling pathways independent of the PD1 pathway.SOLUTION: Provided are an immune checkpoint inhibitor and anticancer drug resistance suppressant, including a kynureninase inhibitor. Also provided are a method for predicting the prognosis of a cancer patient or the sensitivity of a cancer patient to an anticancer drug based on kynureninase activity, and a method for screening genes related to immune checkpoints based on mutual information.SELECTED DRAWING: None

This disclosure provides a method for treating a subject afflicted with a renal cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent may be an anti-angiogenic tyrosine kinase inhibitor or an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody. The disclosure also provides a kit for treating a subject afflicted with a renal cancer, the kit comprising a dosage of an anti-PD-1 antibody, a dosage of another anti-cancer agent which is an anti-angiogenic tyrosine kinase inhibitor or an anti-CTLA-4 antibody, and instructions for using the anti-PD-1 antibody and the other anti-cancer agent in any of the disclosed methods for treating a renal cancer.

Targeting metastasis stem cells through a fatty acid receptor. The disclosure provides the use of blockers or inhibitors of CD36 activity or expression for the treatment of oral squamous cell cancer (OSCC), particularly for the treatment of generated metastases and for diminish is generation from primary tumours. Apart from shRNAs, anti-CD36 antibodies are provided as blockers or inhibitors, especially those that block the binding of CD36 to oxidized LDL and fatty acids and their incorporation into cells, because the promotion of their transport is indicated as the mechanism by which CD36 promote metastases dissemination and growth. Also provided is a method for identifying candidates to anticancer agents, particularly for OSCC metastasis, among those that promote in CD36+ cells, in vivo or in vitro, effects associated to CD36 depletion or blocking such as decrease of growth accumulation of lipid droplets and decrease of size in the case of metastases.

The present disclosure describes methods comprising administering to the subject a therapeutically-effective amount of a pharmaceutical composition and a therapeutically-effective amount of an anti-cancer agent. The disclosed methods can comprise administering a pharmaceutical composition comprising a short chain fatty acid or a pharmaceutically-acceptable salt or ester thereof. The disclosed methods can be used to treat a cancer.

Provided herein are methods related to treating or delaying progression of cancer in an individual. In some embodiments, the methods comprise detecting one or more TMPRSS2-ERG gene rearrangements in one or more samples from an individual having prostate cancer; and administering to the individual an effective amount of a treatment that comprises an anti-cancer agent.

METHODS OF TREATING CANCER BY ADMINISTERING MCL-1 INHIBITORS AND ANTI-CANCER AGENTS SOLUTION: The present disclosure relates generally to methods for treating cancer by administering an MCL-1 inhibitor and an anti-cancer agent. As is explained in detail in the present specification and as is specifically demonstrated, according to the present invention, a remarkable effect is achieved, which could not be easily expected by those skilled in the art from the prior art.SELECTED DRAWING: Figure 5

The present invention relates to a modified mitochondrial comprising, on the outer membrane of the mitochondrial, an antibody that binds to a cancer cell-specific protein and a cytosine deaminase. It is proved that when the mitochondria and 5-FC are jointly used for treating a pancreatic cancer cell line, the cytotoxicity induced by 5-FC treatment is remarkably enhanced. The effect is proved as follows: 5-FC is converted into 5-FU by cytosine deaminase expressed on a mitochondrial outer membrane, so that pancreatic cancer cells are induced to generate apoptosis. Therefore, the modified mitochondria according to the present invention can be effectively used in anticancer therapy using 5-FC as an anticancer agent.

Disclosed are 1,2,4,5-tetraoxane compounds and derivatives thereof having anticancer properties. Disclosed are pharmaceutical compositions and pharmaceutical formulations in unit dosage form suitable for delivering the compounds to a subject in need thereof. In addition to the compounds, the pharmaceutical compositions or formulations can include one or more active agents, such as one or more additional anticancer agents. Also disclosed are methods of treating, mitigating, or treating or ameliorating one or more symptoms associated with cancer in a subject. The methods include (i) administering to a subject in need thereof an effective amount of a compound. The compound can be administered by oral administration, parenteral administration, inhalation, mucosal administration, or a combination thereof. The compound can selectively kill cancer cells and / or cancer stem cells, but not non-cancer cells, by inducing ferroptosis in the cancer cells and / or cancer stem cells.

The present invention relates to a PROTAC compound which can increase the degradation effect of a protein of interest, and to a novel piperidinedione compound which can be used as an E3 enzyme ligand of the PROTAC compound. The piperazinedione derivative compound of the present invention acts on CRBN and thus may be used as a therapeutic agent (for example, an anticancer agent or an immunomodulator) for diseases associated with CRBN proteins.

The present invention relates to a pharmaceutical combination comprising a cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof; and at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor, for use in the treatment of melanoma. The present invention also relates to a method for the treatment of melanoma comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor.

The present invention relates to a composition comprising a CD47-SIRPα blocker and one or more anticancer agents: wherein the CD47-SIRPα blocker is represented by a compound of formula (I). The present invention also relates to a method for treating cancer in a subject by administering a therapeutically effective amount of a CD47-SIRPα blocker represented by formula (I) in combination with one or more anticancer agents.

Aminopyrimidine containing compounds that inhibit both Mer tyrosine kinase (MerTK) activity and Tyro3 kinase activity are disclosed herein. Additionally disclosed are methods of synthesis and use of the aminopyrimidine containing compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents.

The present invention relates to the field of biomedicine. Disclosed herein is interferon-based method and pharmaceutical combination for treating cancer. In particular, the present invention relates to an interferon-based method for treating cancer, comprising i) intermittently administering an interferon-based therapeutic agent, and ii) administering an additional anticancer agent, preferably, Gemcitabine, to a subject, wherein said additional anti-cancer agent is administered after the first administration of said intermittent administration of an interferon-based therapeutic agent. The present invention also relates to a pharmaceutical combination for use in said method.

The present application provides compounds of Formula (I), or a stereoisomer thereof, or a atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of a atropisomer thereof; methods of making the compounds and therapeutic uses thereof. The present application further provides combinations of pharmacologically active agents and pharmaceutical compositions comprising the compounds.

A 5-bromo-2-hydroxy-N′-[(1E)-1-(pyridin-2-yl)ethylidene]benzohydrazide compound, its synthesis, and its use as an anticancer and an antimicrobial agent.

The present disclosure provides a method of treating cancer by administering to an individual in need thereof a pharmaceutical composition comprising a benzenesulfonamide derivative and at least one other therapeutic agent in a different class of anticancer agents.

The present disclosure relates to a composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 and at least one anti-cancer agent. It also relates to a process of preparing the composition and a method / use of the peptide alone or in combination with at least one anti-cancer agent in preventing or managing or treating cancer / precancerous condition.

The present disclosure generally relates to substituted heteroaromatic compounds. The invention relates to novel substituted 4-heteroatom-isoquinolone compounds, and isomers, derivatives, analogues and / or salt forms thereof of formula I; and its process of preparation thereof. Furtherore, the present invention relates to a process of preparation of various drugs / APIs / alkaloids e.g. Ampikin APIs such as CX-614, CX-554, DRF-2655, ITF-296, ITF-1129, Raititrexed, Deoxyvasicinone family of quinazolinone alkaloids, etc. using said formula I compound as starting material. The compound of formula I acts as antimalarial agent, anticancer agent, neuroprotective agent and so on. Formula I

This disclosure relates to hyaluronic acid nanoparticles containing an anticancer agent such as a NADPH oxidase (NOX) inhibitor for targeted delivery to cancerous cells or tumors. In certain embodiments, the nanoparticles are made up of hyaluronic acid conjugated to hydrophobic moieties. In certain embodiments, the hydrophobic moieties are steroid based compounds, such as 5beta-cholanic acid.

Provided herein are methods of treating, preventing, or reducing conditions and / or side effects associated with anti-cancer agents (e.g., chemotherapeutic agents) via administration of a non-naturally occurring melanocortin analog prior to, during, and / or after administration of the anti-cancer agents. The methods reduce adverse effects associated with the anti-cancer agent, such as anorexia, weight loss, muscle mass loss, fat mass loss, wasting, reduced appetite, and loss of appetite, thereby enhancing tolerance of the anti-cancer agents and survival of the subject having cancer or having a disease or condition that is not cancer but is treated, reduced, or prevented by administration of an anti-cancer agent.

Provided is a compound of formula (I)in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and / or lactate dehydrogenase B (LDHB) activity in a cell.

The present invention relates to methods of using herbal extracts in combination with anticancer agents for treating and preventing cancer.

The present invention relates to a combination preparation comprising: an interleukin-2 (IL-2) immune anticancer drug; and a compound represented by chemical formula 1, a stereoisomer thereof, a crystalline form thereof, or a pharmaceutically acceptable salt thereof, whereby the combination preparation can exhibit the effects of enhancing the efficacy of an interleukin-2 immune anticancer drug and alleviating vascular leakage syndrome, which is a side effect of the interleukin-2 immune anticancer drug. [Chemical formula 1]

Provided are methods for treating hematologic malignancy, especially AML-MRC, MDS and / or MM. Specifically, provided are methods for treating AML-MRC and MDS with a compound of formula (I) or a pharmaceutically acceptable salt thereof, optionally in combination with at least one additional anti-cancer agent such as 5-azacitidine or cytarabine, and treating MM with a compound of formula (I) or a pharmaceutically acceptable salt thereof, optionally in combination with at least one additional anti-cancer agent such as pomalidomide, thalidomide, lenalidomide, and / or dexamethasone.

The present invention provides a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof and an anti-cancer agent for the treatment of cancer wherein the compound of formula (I) is a bifunctional compound having G12D mutant KRAS inhibitory activity, and wherein the compound of formula (I) and the anti-cancer agent are as described in the specification.